Literature DB >> 21889114

Association of copy number loss of CDKN2B and PTCH1 with poor overall survival in patients with pulmonary squamous cell carcinoma.

Yushi Zhao1, Ye Li, Hongguang Lu, Jianxin Chen, Zhijie Zhang, Zhong-Zheng Zhu.   

Abstract

BACKGROUND AND
PURPOSE: Although lung cancer is the leading cause of cancer deaths worldwide, reliable markers allowing prediction of patient survival at the time of initial diagnosis are still lacking. Copy number alterations (CNAs) in tumor tissue DNA have been associated with tumorigenesis and malignant progression. We aimed at identification of gene-level CNAs with prognostic value for survival in pulmonary squamous cell carcinoma (SCC).
METHODS: The CNA status of a panel of 44 genes was analyzed by high-resolution array comparative genomic hybridization (CGH) in 49 SCC samples. Overall survival information (median follow-up, 40 months) for the patients was collected and used to assess outcome correlations with gene CNAs.
RESULTS: Survival analysis showed that both CDKN2B loss and PTCH1 loss were associated with poor survival (both P < .001, log-rank test). Multivariate Cox analysis, including CDKN2B loss and PTCH1 loss as well as age, sex, cigarette smoking status, tumor size, tumor differentiation, and TNM stage showed that CDKN2B loss (hazard ratio [HR], 17.88; 95% confidence interval [CI], 4.40-72.67; P < .001) and PTCH1 loss (HR, 10.81; 95% CI, 1.92-60.98; P = .007) were independent prognostic factors for poor survival. In addition the PTCH1 loss was more frequently found in moderately or poorly differentiated tumors than in well-differentiated tumors (P = .007).
CONCLUSION: These findings suggest that 2 genes of loss, CDKN2B and PTCH1, are associated with poor overall survival in patients with SCC of the lung and may be useful as prognostic markers.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21889114     DOI: 10.1016/j.cllc.2011.02.007

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  6 in total

1.  Loss of RUNX1 is associated with aggressive lung adenocarcinomas.

Authors:  Jon Ramsey; Kelly Butnor; Zhihua Peng; Tim Leclair; Jos van der Velden; Gary Stein; Jane Lian; C Matthew Kinsey
Journal:  J Cell Physiol       Date:  2017-11-01       Impact factor: 6.384

2.  A Sonic Hedgehog Pathway Score to Predict the Outcome of Resected Non-Small Cell Lung Cancer Patients.

Authors:  Carlos Camps; Eloísa Jantus-Lewintre; Alejandro Herreros-Pomares; Paula Doria; Sandra Gallach; Marina Meri-Abad; Ricardo Guijarro; Silvia Calabuig-Fariñas
Journal:  Ann Surg Oncol       Date:  2022-09-21       Impact factor: 4.339

3.  Genomic Features of Solid Tumor Patients Harboring ALK/ROS1/NTRK Gene Fusions.

Authors:  Yinghuan Dai; Ping Liu; Wenlong He; Lizhen Yang; Yang Ni; Xuejiao Ma; Furong Du; Chao Song; Yang Liu; Yi Sun
Journal:  Front Oncol       Date:  2022-06-16       Impact factor: 5.738

4.  Specific copy number changes as potential predictive markers for adjuvant chemotherapy in non-small cell lung cancer.

Authors:  Mitsuo Sato
Journal:  Transl Lung Cancer Res       Date:  2018-12

5.  Impact of Concurrent Genomic Alterations Detected by Comprehensive Genomic Sequencing on Clinical Outcomes in East-Asian Patients with EGFR-Mutated Lung Adenocarcinoma.

Authors:  Seijiro Sato; Masayuki Nagahashi; Terumoto Koike; Hiroshi Ichikawa; Yoshifumi Shimada; Satoshi Watanabe; Toshiaki Kikuchi; Kazuki Takada; Ryota Nakanishi; Eiji Oki; Tatsuro Okamoto; Kouhei Akazawa; Stephen Lyle; Yiwei Ling; Kazuaki Takabe; Shujiro Okuda; Toshifumi Wakai; Masanori Tsuchida
Journal:  Sci Rep       Date:  2018-01-17       Impact factor: 4.379

6.  Identification of dysregulated long non-coding RNAs/microRNAs/mRNAs in TNM I stage lung adenocarcinoma.

Authors:  Ziqiang Tian; Shiwang Wen; Yuefeng Zhang; Xinqiang Shi; Yonggang Zhu; Yanzhao Xu; Huilai Lv; Guiying Wang
Journal:  Oncotarget       Date:  2017-06-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.